Vancomycin-resistant enterococcal infections

New England Journal of Medicine

Volumn 342, Issue 10, 2000, Pages 710-721

  Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; GENTAMICIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; BINDING AFFINITY; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; ENZYME ACTIVITY; HOSPITAL INFECTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; TRANSPOSON;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COLONY COUNT, MICROBIAL; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENTEROCOCCUS; FLUOROQUINOLONES; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LACTAMS; VANCOMYCIN RESISTANCE;

EID: 0034058528     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003093421007     Document Type: Review

References (148)

1. Hoffmann SA, Moellering RC Jr. The enterococcus: "putting the bug in our ears." Ann Intern Med 1987;106:757-61.
2. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.
3. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
4. Shay DK, Goldmann DA, Jarvis WR. Reducing the spread of antimicrobial resistant microorganisms: control of vancomycin-resistant enterococci. Pediatr Clin North Am 1995;42:703-16.
5. Moreno F, Grota P, Crisp C, et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in Southern Texas. Clin Infect Dis 1995;21:1234-7.
6. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
7. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:Suppl 3B:72S-75S.
8. Morrison AJ Jr, Wenzel RP. Nosocomial urinary tract infections due to enterococcus: ten years' experience at a university hospital. Arch Intern Med 1986;146:1549-51.
9. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988;67:248-69.
10. Iwen PC, Kelly DM, Linder J, et al. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period. Antimicrob Agents Chemother 1997;41:494-5.
11. Facklam RR, Sahm DA. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, D.C.: American Society of Microbiology, 1995:308-14.
12. Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering RC Jr. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992;36:121-5.
13. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990;34:1792-4.
14. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995;274:1706-13.
15. Mederski-Samoraj BD, Murray BE. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis 1983;147:751-7.
16. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993;7:117-33.
17. Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, Chow JW. A new high-level gentamicin resistance gene, aph2″-Id, in Enterococcus spp. Antimicrob Agents Chemother 1998;42:1229-32.
18. Murray BE. β-Lactamase-producing enterococci. Antimicrob Agents Chemother 1992;36:2355-9.
19. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Vol. 17. Villanova, Pa.: National Committee for Clinical Laboratory Standards, 1997:1-29. (Publication no. M7-A4.)
20. Fontana R, Ligozzi M, Pittaluga F, Sana G. Intrinsic penicillin resistance in enterococci. Microb Drug Resist 1996;2:209-13.
21. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998;178:159-63.
22. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-54.
23. Fines M, Perichon B, Reynolds P, Sahm DF, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999;43:2161-4.
24. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide resistant Enterococcus faecalis BM4339. Antimicrob Agents Chemother 1997;41: 2016-8.
25. Leclercq R, Derlot E, Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1989;33:10-5.
26. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;93:195-8.
27. Carias LL, Rudin SD, Donskey CJ, Rice LB. Generic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecalis isolate. J Bacteriol 1998;180:4426-34.
28. Hayden MK, Trenholme GM, Schultz JE, Sahm DE In vivo development of teicoplanin resistance in a VanB Enterococcus faecalis isolate. J Infect Dis 1993;167:1224-7.
29. Aslangul E, Baptista M, Fantin B, et al. Selection of glycopeptide-resistant mutants of VanB type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997;175:598-605.
30. Navarro F, Courvalin P. Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens. Antimicrob Agents Chemother 1994;38:1788-93.
31. Mevius D, Devriese L, Butaye P, Vandamme P, Verschure M, Veldman K. Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB, and both vanA and vanB genotypes from faecal samples of veal calves in the Netherlands. J Antimicrob Chemother 1998;42:275-6.
32. Rippere K, Patel R, Uhl JR, et al. DNA sequence resembling vanA and vanB in the vancomycin-resistant biopesticide Bacillus popilline. J Infect Dis 1998;178:584-8.
33. Evers S, Quintiliani R Jr, Courvalin P. Genetics of glycopeptide resistance in entcrococci. Microb Drug Resist 1996;2:219-23.
34. Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11-6.
35. Arthur M, Depardieu F, Gerbaud G, Galimand M, Leclercq R, Courvalin P. The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn 1546 and related elements in the absence of induction. J Bacteriol 1997;179:97-106.
36. Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991;30: 10408-15.
37. Arthur M, Depardieu F, Cabanie L, Reynolds P, Courvalin P. Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci. Mol Microbiol 1998;30:819-30.
38. Satake S, Clark N, Rimland D, Nolte FS, Tenover FC. Detection of vancomycin-resistant enterococci in fecal samples by PCR. J Clin Microbiol 1997;35:2325-30.
39. Heaton MP, Discotto LF, Pucci MJ, Handwerger S. Mobilization of vancomycin resistance by transposon-mediated fusion of a VanA plasmid with an Enterococcus faecium sex pheromone-response plasmid. Gene 1996; 171:9-17.
40. Poyart C, Pierre C, Qucsne G, Pron B, Berche P, Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 1997;41:24-9.
41. Quintiliani R Jr, Courvalin P. Characterization of Tn1547, a composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM4281. Gene 1996;172:1-8.
42. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
43. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
44. Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989;33:1588-91.
45. Jones RN, Sader HS, Erwin ME, Anderson SC, Enterococcus Study Group. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1995;21:85-93.
46. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40: 2605-9.
47. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13. [Erratum, Infect Control Hosp Epidemiol 1995;16:498.]
48. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173: 1129-36.
49. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
50. Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
51. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.
52. Bradley SJ, Wilson ALT, Allen MC, Sher HA, Goldstonc AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261-6.
53. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-72.
54. Weinstein JW, Roc M, Towns M, et al. Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996;17:36-41.
55. Dever LL, China C, Eng RHK, O'Donovan C, Johanson WG Jr. Van comycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: association with antibiotic usage. Am J Infect Control 1998;26:40-6.
56. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
57. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
58. Bonten MJM, Slaughter S, Ambergen SW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127-32.
59. Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-53.
60. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-5.
61. Orr KE, Gould FK, Perry ID, et al. Therapeutic beds: the Trojan horses of the 1990s? Lancet 1994;344:65-6.
62. Brooks S, Khan A, Stoica D, et al. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect Control Hosp Epidemiol 1998;19:333-6.
63. Schoonmaker DJ, Bopp LH, Baltch AL, Smith RP, Rafferty ME, George M. Genetic analysis of multiple vancomycin-resistant Enterococcus isolates obtained serially from two long-term-care patients. J Clin Microbiol 1998;36:2105-8.
64. Mato R, de Lencastre H, Roberts RB, Tomasz A. Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospital. Microb Drug Resist 1996;2:309-17.
65. Pegues DA, Pegues CF, Hibberd PL, Ford DS, Hooper DC. Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital. J Clin Microbiol 1997;35:1565-70.
66. Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448-56.
67. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1994;34:515-28.
68. van den Bogaard AE, Jensen LB, Stobberingh EE. Vancomycin-resistant enterococci in turkeys and farmers. N Engl J Med 1997;337:1558-9.
69. Klare I, Heier H, Claus H, Reissbrodt R, Witte W. vanA-Mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995;125:165-71. [Erratum, FEMS Microbiol Lett 1995;127:273.]
70. Aarestrup FM, Ahrens P, Madsen M, Pallesen LV, Poulsen RL, Westh H. Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster. Antimicrob Agents Chemother 1996;40:1938-40
71. Witte W, Klare I. Glycopeptide-rcsistant Enterococcus faecium outside hospitals: a commentary. Microb Drug Resist 1995;1:259-63.
72. Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Morris JG Jr. Isolation of vancomycin-resistant enterococci from animal feed in USA. Lancet 1999;353:722.
73. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42:1303-4.
74. Bingen EH, Denamur E, Lambert-Zechovsky NY, Elion J. Evidence for the genetic unrelatedness of nosocomial vancomycin-resistant Enterococcus faecium strains in a pediatric hospital. J Clin Microbiol 1991;29:1888-92
75. Jensen LB, Ahrens P, Dons L, Jones RN, Hammerum AM, Aarestrup FM. Molecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humans. J Clin Microbiol 1998;36:437-42.
76. Quintiliani R Jr, Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett 1994;119:359-63.
77. Woodford N, Adebiyi AM, Palepou MF, Cookson BD. Diversity of VanA glycopeptide resistance elements in enterococci from humans and nonhuman sources. Antimicrob Agents Chemother 1998;42:502-8.
78. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother 1993;37:2311-7.
79. Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinu pristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998;26:1460-1.
80. Losonsky GA, Wolf A, Schwalbe RS, Nataro J, Gibson CB, Lewis EW. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994;19:163-5.
81. Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997;40:144-5.
82. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
83. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:249 53.
84. Montecalvo MA, Horowitz H, Wormser GP, Seiter K, Carbonaro CA. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1995;39:794.
85. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mor tality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
86. Linden PK, Pasculle AW, Manez R, et al Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
87. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996;156:1458-62.
88. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995;20:296-301.
89. Landry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 1989;17:323-9.
90. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
91. Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439-42
92. Wade JJ, Rolando N, Williams R, Casewell MW. Serious infections caused by multiply-resistant Enterococcus faecium. Microb Drug Resist 1995;1:241-3.
93. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997;25:1269-70.
94. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J. Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991;35:92-8.
95. Caron F, Pestel M, Kitzis MD, Lemeland JF, Humbert G, Gutmann L. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995;171:106-12.
96. Cercenado E, Eliopoulos GM, Wennersten CB, Moellering RC Jr. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992;36:2201-3.
97. Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 1996;173:909-13.
98. Pestel M, Martin E, Aucouturier C, Lemeland JF, Caron F. In vitro interactions between different β-lactam antibiotics and fosfomycin against bloodstream isolates of enterococci. Antimicrob Agents Chemother 1995; 39:2341-4.
99. Korten V, Huang WM, Murray BE. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1994;38:2091-4.
100. Korten V, Tomayko JF, Murray BE. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob Agents Chemother 1994;38:611-5.
101. Zhanel GG, Karlowsky JA, Hoban DJ. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species. Diagn Microbiol Infect Dis 1998;31: 343-7
102. Cohen MA, Yoder SL, Huband MD, Roland GE, Courtney CL. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci. Antimicrob Agents Chemother 1995;39:2123-7.
103. Rambaldi M, Ambrosone L, Migliaresi S, Rambaldi A. Combination of co-trimoxazole and ciprofloxacin as therapy of a patient with infective endocarditis caused by an enterococcus highly resistant to gentamicin. J Antimicrob Chemother 1997;40:737-8.
104. Sacher HL, Miller WC, Landau SW, Sacher ML, Dixon WA, Dietrich KA. Relapsing native-valve enterococcal endocarditis: a unique cure with oral ciprofloxacin combination drug therapy. J Clin Pharmacol 1991;31: 719-21.
105. Tripodi MF, Locatelli A, Adinolfi LE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998;17:734-6.
106. Ingerman M, Pitsakis PG, Rosenberg A, et al. β-Lactamase production in experimental endocarditis due to aminoglycoside resistant Streptococcus faecalis. J Infect Dis 1987;155:1226-32.
107. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus foecium. Antimicrob Agents Chemother 1993;37:2069-73.
108. Landman D, Quale JM, Mobarakai N, Zaman MM. Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrugresistant Enterococcus faecium. J Antimicrob Chemother 1995;36:253-8.
109. Zaman MM, Landman D, Burney S, Quale JM. Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with clinafloxacin and penicillin. J Antimicrob Chemother 1996;37:127-32.
110. Lautenbach E, Schuster MG, Biker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-65.
111. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760-6.
112. Perez Mato S, Robinson S, Begue RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr Infect Dis J 1999;18:483-4.
113. Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994; 20:41-3.
114. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998;27: 1554-6.
115. Taylor SE, Paterson DL, Yu VL. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur J Clin Microbiol Infect Dis 1998;17:798-800.
116. Allcrberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999;43:211-7.
117. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC Jr, Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41:2749-53.
118. Rende-Fournier R, Leclercq R, Galimand M, Duval J, Courvalin P. Identification of the sat A gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother 1993; 37:2119-25.
119. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998;42:2710-7.
120. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994;344:1025-6.
121. Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist 1995;1:95-6.
122. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39:145-51.
123. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999;44:251-61.
124. Furlong WB, Rakowski TA. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. Clin Infect Dis 1997;25:163-4.
125. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother 1997;41:931-5.
126. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-7.
127. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689-90.
128. Montecalvo MA, Shay DK, Gedris C, et al. A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: colonized patients pose an infection control risk. Clin Infect Dis 1997;25: 929-30
129. Beezhold DW, Slaughter S, Hayden MK, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704-6.
130. Roghmann MC, Qaiyumi S, Johnson JA, Schwalbe R, Morris JG Jr. Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. Clin Infect Dis 1997;24:514-5.
131. Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-54.
132. Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-5.
133. Brennen C, Wagener MM, Muder RR. Vancomycin-resistant Enterococcus faecium in a long-term care facility. J Am Geriatr Soc 1998;46:157 60.
134. Dever LL, Handwerger S. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. Microb Drug Resist 1996; 2:415-21.
135. Whitman MS, Pitsakis PG, DeJesus E, Osborne AJ, Levison ME, Johnson CC. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Antimicrob Agents Chemother 1996;40:1526-30.
136. O'Donovan CA, Fan-Havard P, Tecson-Tumang FT, Smith SM, Eng RH. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis 1994;18:105-9.
137. Chia JKS, Nakata MM, Park SS, Lewis RP, McKee B. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995;21:1520.
138. Weinstein MR, Dedier H, Brunton J, Campbell I, Conly JM. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1999;29:361-6.
139. McGeer A, Cann D, Mustachi B, Willey B, Wigston C, Low DE. Evaluation of oral bacitracin therapy for the eradication of colonization of resistant enterococci. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:283. abstract.
140. Montecalvo MA, Raffalli J, Rodney K, Petrullo C, Jarvis WR, Wormser GP. Effect of oral bacitracin (B) on the number of vancomycin resistant enterococci (VRE) in stool. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 28-October 1,1997. Washington, D.C.: American Society for Microbiology, 1997:303. abstract.
141. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC, Jr. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993;37:1364-6.
142. Anglim AM, Klym B, Byers KE, Scheld WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997;157: 1132-6.
143. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996;17:356-9.
144. Kim W-J, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. I Infect Dis 1999;179: 163-71.
145. Byers KE, Durbin LJ, Simonton MB, Anglim AM, Adal KA, Farr BM. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998;19:261-4.
146. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020 5.
147. Boyce JM, Mermel LA, Zervos MJ, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634 7. [Erratum, Infect Control Hosp Epidemiol 1996;17:211.]
148. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients Clin Infect Dis 1995;21: 45-50.